Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » About Us » Our Staff » John Gilmore

John Gilmore

Staff Reporter
Phone Number
212-651-5628
Email
[email protected]

Articles Authored by John Gilmore

Jun 29, 2020

Creatv MicroTech Aims to Detect Patient Immune Cells for Cancer Drug Response Prediction

Premium

The firm initially plans to apply the method, which measures the size of specific macrophages in blood, to predict lung cancer immunotherapy response.

Jun 25, 2020

Inivata Demonstrates Potential of ctDNA Assay for Cancer Recurrence, MRD Applications

Premium

In one study, the UK-based firm found that its RaDaR assay detected circulating tumor DNA in lung cancer patients up to a year before standard clinical progression occurred in most of the cases. 

Jun 23, 2020

Patient-Specific ctDNA Detection Method Could Improve MRD Monitoring for Cancer Recurrence

Premium

The technique, called INVAR, applies error-suppression methods and signal enrichment to analyze hundreds of loci to detect circulating tumor DNA in blood samples.

Jun 18, 2020

Israeli Startup Curesponse Targets European Pharma Market With Drug Prediction, Development Service

Premium

The firm's technology uses ex vivo organ culture to model cancer growth and predict a patient's tumor response to chemotherapy and targeted drugs. 

Jun 12, 2020

Liquid Biopsy Startup C2i Genomics to Launch International Validation Trials for MRD Detection Tech

Premium

The company is commercializing a genome-wide sequencing method called MRDetect, developed by researchers at the New York Genome Center and Weill Cornell Medicine. 

Jun 05, 2020

University of Utah Spinout Eigengene Developing Genome-Wide Signatures for Cancer Diagnostics

Premium

Launched in 2016 by researchers in Utah, the firm recently published a genome-wide signature that predicts survival of glioblastoma patients. 

Jun 02, 2020

Tiziana Life Sciences to Launch Spinoff to Market Breast Cancer Recurrence Assay in Europe

Premium

The firm presented a poster at ASCO suggesting that its StemPrintER platform outperforms Exact Science's Oncotype Dx for predicting breast cancer recurrence.

May 29, 2020

Lucence Dx Liquid Biopsy Tech Detects Structural Rearrangements, Breast Cancer Mutations

Premium

In the near term, the firm will launch a laboratory-developed, late-stage lung cancer assay out of its lab in Palo Alto. 

May 20, 2020

Bio-Techne Bets Clinical Utility Study Data Will Sway Payors to Cover Prostate Cancer Risk Test

Premium

The Minneapolis-based firm believes the assay can successfully serve as a clinical indicator for patients at risk of developing high-grade prostate cancer (HGPC), thereby improving prostate cancer management. 

May 19, 2020

Israel's Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays

Premium

The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.

The Scan

Working Out the Effect

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Increased Genetic Privacy in Florida

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

Attention-Grabbing in Two Ways

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

Nature Papers Describe CRISPR Plant Editing Methods, DNA-PAINT Improvements, More

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.